Announcing the results of the 2026 INFORMS Board of Directors election and the new board for 2027.
INFORMS has named 12 distinguished leaders as the 2026 class of INFORMS Fellows, one of the highest honors in the profession.
Most medical devices do not hit the market through rigorous safety testing but by being deemed similar enough to something already approved—the “predicate” device through a mechanism known as the FDA’s 510(k) pathway. But similar is not a synonym for safe. While the assumption may be that substantial equivalence is a reasonable stand-in for a safety review, a share of devices cleared with this method still get recalled, and the FDA spends valuable time reviewing devices the same way, regardless of how risky it is on paper.
An audio journey of how data and analytics save lives, save money and solve problems.
Jeff Cohen
Chief Strategy Officer
INFORMS
Catonsville, MD
[email protected]
443-757-3565
Explore our resources for multiple topics including:
Joe Biden will be the 46th president and that the Democrats have held onto the House. With the Election Day dust now settled, let’s take a look at the winners and losers, courtesy of the data.
The airline industry has been a major beneficiary of the vaccine euphoria. First Pfizer, then Moderna announced vaccine candidates with a promised effectiveness of 90% or more. This excited investors and airline executives alike, with visions of pent-up demand creating packed planes with filled middle seats.
Another wave of COVID-19 cases is now triggering another wave of panic buying across the country. But the Maryland Department of Commerce says it has no regulatory oversight on grocers in the state. At this point, it's up to each individual company to set purchasing limits on high-demand items. In some instances, stores are starting to see empty shelves again.
Scientists work at the mAbxience biosimilar monoclonal antibody laboratory plant in Garin, Buenos Aires province, on August 14, 2020, where an experimental coronavirus vaccine will be produced for Latin America. - Argentina will manufacture while Mexico will pack and distribute in Latin America, except of Brazil, the vaccine against COVID-19 developed by the University of Oxford and the AstraZeneca laboratory.
Two drug companies have now reported highly successful results from phase III trials of COVID-19 vaccines. On November 18 Pfizer and partner BioNTech said their vaccine was 95 percent effective at preventing the disease, based on full trial results. Two days earlier Moderna reported its vaccine was 94.5 percent effective, based on interim data.
OR/MS Today is the INFORMS member magazine that shares the latest research and best practices in operations research, analytics and the management sciences.
Access OR/MS Today Magazine
Analytics magazine showcases articles and research reports based on big data, AI, machine learning, data analytics and other new-age technologies.
Access Analytics Magazine